- Home
- BVFL vs ATAI Comparison
BVFL vs ATAI Comparison
Compare BVFL & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- ATAI
- Stock Information
- Founded
- BVFL 1873
- ATAI 2018
- Country
- BVFL United States
- ATAI Germany
- Employees
- BVFL N/A
- ATAI N/A
- Industry
- BVFL Savings Institutions
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- BVFL Finance
- ATAI Health Care
- Exchange
- BVFL Nasdaq
- ATAI Nasdaq
- Market Cap
- BVFL 205.3M
- ATAI 214.8M
- IPO Year
- BVFL N/A
- ATAI 2021
- Fundamental
- Price
- BVFL $17.30
- ATAI $1.24
- Analyst Decision
- BVFL
- ATAI Strong Buy
- Analyst Count
- BVFL 0
- ATAI 4
- Target Price
- BVFL N/A
- ATAI $9.00
- AVG Volume (30 Days)
- BVFL 56.0K
- ATAI 1.3M
- Earning Date
- BVFL 01-21-2025
- ATAI 11-13-2024
- Dividend Yield
- BVFL N/A
- ATAI N/A
- EPS Growth
- BVFL N/A
- ATAI N/A
- EPS
- BVFL 1.20
- ATAI N/A
- Revenue
- BVFL $38,028,000.00
- ATAI $331,000.00
- Revenue This Year
- BVFL N/A
- ATAI $93.15
- Revenue Next Year
- BVFL N/A
- ATAI N/A
- P/E Ratio
- BVFL $14.50
- ATAI N/A
- Revenue Growth
- BVFL 0.50
- ATAI N/A
- 52 Week Low
- BVFL $10.14
- ATAI $1.03
- 52 Week High
- BVFL $18.19
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- BVFL 55.84
- ATAI 33.95
- Support Level
- BVFL $17.52
- ATAI $1.15
- Resistance Level
- BVFL $18.19
- ATAI $1.69
- Average True Range (ATR)
- BVFL 0.44
- ATAI 0.11
- MACD
- BVFL -0.05
- ATAI -0.06
- Stochastic Oscillator
- BVFL 38.16
- ATAI 3.69
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. It offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, business checking as well as certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.